



Additional Products Impacted by Average Manufacturer Price Medicaid Rebate Cap (AMP-Cap) Removal

Good afternoon everyone,

As you know, in 2023 several pharmaceutical manufacturers began announcing significant pricing changes to their products in response to recent regulatory and industry pressures stemming from the implementation of the American Rescue Plan Act of 2021, along with changes made to eliminate the Medicaid Rebate Cap starting January 1, 2024. As a result of the unanticipated industry wide changes, Optum Rx determined that rebate guarantees needed to be adjusted.

Optum Rx has been closely monitoring drug pricing changes and there have been additional manufacturers who have announced pricing changes to the following products:

- Symbicort
- Victoza
- Advair HFA
- Xyosted
- Copaxone
- Pradaxa
- Finacea
- Servant Dis
- Invokana

After close evaluation and consideration, Optum Rx has determined from the list of impacted products above, the drug price changes on the ***following products*** require a rebate credit adjustment effective 1/1/2024.

- Symbicort
- Victoza
- Advair HFA

The updated rebate adjustment will be made in an equitable manner in consideration of this continued impact of an industry wide event.

Financial Modeling

We are attaching supporting financial documentation for these impacted drugs in 2024 for your review. Any and all future financial impact analysis modeling shared is meant to be directional and is subject to change.

Next Steps

Optum Rx will continue to provide updates on any other manufacturer changes and will communicate rebate and other changes that may impact your financial guarantees as information becomes available in this evolving environment.

Please ensure that the information in this email and financial modeling is shared with any additional stakeholders within Segal who I may have missed.

Sincerely,

Holly Agoney

EXT COMM, FID 1008	Ingredient Cost Current	Ingredient Cost Future	Ingredient Cost Difference	Rebate Current	Rebate Future	Rebate Difference	Net Cost Current	Net Cost Future	Net Cost Difference
ADVAIR HFA	\$11,230	\$9,052	(\$2,178)	\$0	\$0	\$0	\$11,230	\$9,052	(\$2,178)
SYMBICORT	\$3,202	\$1,921	(\$1,281)	\$0	\$0	\$0	\$3,202	\$1,921	(\$1,281)
VICTOZA	\$3,173	\$2,224	(\$949)	\$0	\$0	\$0	\$3,173	\$2,224	(\$949)
Total	\$17,605	\$13,197	(\$4,408)	\$0	\$0	\$0	\$17,605	\$13,197	(\$4,408)

Disclaimer:

The data listed above is annualized based on 2024 Q1 claim data.

Please note that any summaries provided to you are only estimates, and should not be viewed as any representation by Optum that any provided projections are confirmed and final.

Clients should use utmost caution in relying on these projections, including with respect to any current or future bid submissions to CMS. Additionally, Client is not obligated to follow any formulary recommendations and Client remains solely responsible for all benefit design decisions.